Center for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, WA, USA.
Department of Pediatrics, Division of Genetic Medicine, University of Washington, Seattle, WA, USA.
Transl Vis Sci Technol. 2024 Jul 1;13(7):7. doi: 10.1167/tvst.13.7.7.
Lipid nanoparticles (LNPs) show promise in their ability to introduce mRNA to drive protein expression in specific cell types of the mammalian eye. Here, we examined the ability of mRNA encapsulated in LNPs with two distinct formulations to drive gene expression in mouse and human retina and other ocular tissues.
We introduced mRNA-carrying LNPs into two biological systems. Intravitreal injections were tested to deliver LNPs into the mouse eye. Human retinal pigment epithelium (RPE) and retinal explants were used to assess mRNA expression in human tissue. We analyzed specificity of expression using histology, immunofluorescence, and imaging.
In mice, mRNAs encoding GFP and ciliary neurotrophic factor (CNTF) were specifically expressed by Müller glia and RPE. Acute inflammatory changes measured by microglia distribution (Iba-1) or interleukin-6 (IL-6) expression were not observed 6 hours post-injection. Human RPE also expressed high levels of GFP. Human retinal explants expressed GFP in cells with apical and basal processes consistent with Müller glia and in perivascular cells consistent with macrophages.
We demonstrated the ability to reliably transfect subpopulations of retinal cells in mouse eye tissues in vivo and in human ocular tissues. Of significance, intravitreal injections were sufficient to transfect the RPE in mice. To our knowledge, we demonstrate delivery of mRNA using LNPs in human ocular tissues for the first time.
Ocular gene-replacement therapies using non-viral vector methods are a promising alternative to adeno-associated virus (AAV) vectors. Our studies show that mRNA LNP delivery can be used to transfect retinal cells in both mouse and human tissues without inducing significant inflammation. This methodology could be used to transfect retinal cell lines, tissue explants, mice, or potentially as gene-replacement therapy in a clinical setting in the future.
脂质纳米颗粒(LNPs)在将 mRNA 导入哺乳动物眼中特定细胞类型以驱动蛋白质表达方面显示出巨大潜力。在此,我们研究了两种不同配方的包裹 mRNA 的 LNPs 在小鼠和人视网膜及其他眼组织中驱动基因表达的能力。
我们将携带 mRNA 的 LNPs 引入两个生物系统。通过眼内注射测试将 LNPs 递送至小鼠眼内。用人视网膜色素上皮(RPE)和视网膜外植体评估人组织中的 mRNA 表达。我们通过组织学、免疫荧光和成像分析来评估表达的特异性。
在小鼠中,编码 GFP 和睫状神经营养因子(CNTF)的 mRNAs 特异性地由 Müller 胶质细胞和 RPE 表达。注射后 6 小时,通过微胶质细胞分布(Iba-1)或白细胞介素-6(IL-6)表达测量,未观察到急性炎症变化。人 RPE 也高表达 GFP。人视网膜外植体在具有顶和基底突起的细胞中表达 GFP,这些细胞与 Müller 胶质细胞一致,在血管周围细胞中表达 GFP,这些细胞与巨噬细胞一致。
我们证明了在体内和人眼组织中可靠地转染小鼠眼组织中视网膜细胞亚群以及在人眼组织中转染 GFP 的能力。重要的是,眼内注射足以转染小鼠的 RPE。据我们所知,我们首次在人眼组织中使用 LNPs 递送电信使 RNA。
使用非病毒载体方法的眼部基因替代疗法是腺相关病毒(AAV)载体的有前途的替代方法。我们的研究表明,mRNA LNP 递送可用于转染小鼠和人组织中的视网膜细胞,而不会引起明显的炎症。该方法可用于转染视网膜细胞系、组织外植体、小鼠,或在未来的临床环境中用作基因替代疗法。